drugset
drugset / Trial / NCT06171048

Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects

NCT06171048 ↗

Phase 1 Unknown 236 enrolled Keymed Biosciences Co.Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.

Timeline

Start
2024-04-30
Primary completion
2025-04-30
Completion
2025-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CM310 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.